CSPC Baike (Shandong) Biopharmaceutical
Clinical trials sponsored by CSPC Baike (Shandong) Biopharmaceutical, explained in plain language.
Pharmaceutical subsidiary of CSPC Group, developing biologics.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Healthy volunteers needed to test new injection method for experimental drug Results expected Oct 2026 (estimated)
-
New asthma drug aims to cut severe attacks in half
Disease control Recruiting nowThis Phase 3 trial tests an injectable drug called CM326 in 230 adults with moderate to severe asthma. The goal is to see if it can reduce the number of severe asthma attacks over one year. Participants will receive either CM326 or a placebo, and researchers will also measure cha…
Phase 3 • Sponsor: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New Weight-Loss drug SYH9017 enters human testing in china
Disease control Recruiting nowThis early-stage trial tests a new drug called SYH9017 in 66 Chinese adults who are overweight or obese. The main goal is to check the drug's safety and how the body processes it after single and multiple doses. Participants will receive either the drug or a placebo, and research…
Phase 1 • Sponsor: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC